Back to Article List
ACORDA OPENS CORPORATE HEADQUARTERS IN GREENBURGH TODAY... A NEW RESTAURANT OPENS IN ARDSLEY
Release Date: July 19, 2012
Acorda Therapeutics dedicates new corporate headquarters in Greenburgh this afternoon!
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will officially open their new corporate headquarters at the Ardsley Park life science campus in unincorporated Greenburgh this afternoon -near Ardsley, New York. The new facility, which is leased from BioMed Realty Trust, Inc. (NYSE: BMR), includes approximately 138,000 square feet of office and state-of-the-art laboratory space. Acorda has relocated all employees from its former location in Hawthorne, New York to the new Greenburgh/Ardsley facility. The town of Greenburgh is thrilled to welcome this new bio tech company to our town. They are joining a number of other bio tech companies that are already located in Greenburgh. Acorda Therapeutics will join Seimans, Beyer, Epicept, Profectus Biosciences, Progenetics Pharmeceuticles, PsychoGenics, Regeneron Pharmaceuticles, Apex Laboratory,Additives Division, Standards Research Services I International, CCS Research Inc & Biomed Pharmaceuticals and other companies that have chosen to locate in Greenburgh! We believe that Greenburgh is becoming the bio tech capitol of the region.
“Acorda moved to Westchester in 1998 as a small start-up biotechnology company with six employees, and I’m very proud of what our associates have accomplished in the ensuing years. We’ve brought an important new therapy to market AMPYRA, which has helped tens of thousands of people with multiple sclerosis. That in turn has helped us grow our Company to become a leader in developing neurological medicines, with more than 340 associates, including 200 based in Ardsley,” said Ron Cohen, M.D., Acorda’s President and CEO. “As a native New Yorker, it is also gratifying to contribute to the expanding biotechnology presence in Westchester County. Westchester has the resources we need, in particular a highly educated and skilled workforce, to continue to grow and pursue our goal to develop therapies that improve the lives of people living with MS, stroke, spinal cord injury, and other neurological conditions.”
Acorda’s partnership with Empire State Development Corporation, County of Westchester Industrial Development Agency (IDA), New York State Energy Research and Development Authority (NYSERDA) and the County of Westchester, New York produced an economic incentive package that made the move economically feasible for the Company, while promoting the retention of existing jobs and creation of new jobs in New York. Acorda will receive tax credits of up to $5.2 million as part of the New York State Excelsior Jobs Program, an employment-creation initiative administered by Empire State Development. Acorda is also eligible for various tax credits of up to $1.15 million through the County of Westchester IDA and for additional incentives through NYSERDA.
Purchased by BioMed Realty in 2011, the Ardsley Park life science campus comprises approximately 160,500 square feet of laboratory and office space and 500,000 square feet of future redevelopment and development potential that can accommodate multiple tenants. BioMed Realty successfully completed an extensive renovation of the property since acquiring the property.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.
Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.
Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.
NEW RESTAURANT OPENS IN ARDSLEY—Good news. A new restaurant just opened up in Ardsley. If you love greek and American food, try the Downtown Restaurant out! It’s important for the community to support our local businesses and to thank them for being here for us!
731 Saw Mill River Road
Ardsley, NY 10502
site of the former Captain Video store in the Astoria Federal building.
Greek and American food.
We are pleased to offer home-cooked food prepared from scratch using fresh ingredients.
All desserts are home made from our family favorite recipes, except ice cream and yogurt.
Take out available 693 5800. Steve Vagianos is the owner. We wish him the best of luck.